PPT-Mitigating Stroke Risk in TAVR:

Important Considerations as TAVR Moves to LowerRisk Patients Benjamin Z Galper MD MPH Brigham amp Womens Hospital Boston MA Consequences of Stroke Mortality TAVR patients suffering a VARC2 disabling stroke have significantly higher mortality rates compared to patients without stroke 1year mortality of 67 vs 12 and 2year mortality of 83 vs 20. 1 cause of stroke Know your blood pressure and have it checked at least once every two years If its consistently 14090 or above its high Talk to your doctor about how to manage it 4AUE Tobacco use damages blood vessels Dont smoke and avoid secondhan A Prospective Randomized Evaluation of the . TriGuard. Embolic . DEFLECT. ion. Device during Transcatheter Aortic Valve Replacement . Alexandra Lansky, MD. Yale . University School of Medicine. New Haven, CT. Ron Pellegrino, MD. November 20, 2015. Objectives. Become comfortable with risk factor modification and chronic management of the post stroke patient.. Review the major modifiable risk factors. HTN guidelines for long term management of ischemic stroke. Professor & Vice-Chairman Department of Neurosurgery. Director Neurosurgical Stroke Service, . Kaleida. Health. Chief Medical Officer, Jacobs Institute. Presenting endorsed statement from. American Association of Neurological Surgeons (AANS). Program Goals. Thromboembolic Risk Associated With TAVR. Timing of Stroke and Bleeding Post TAVR. Stroke After TAVR -- Pathophysiology. TAVR and AF Background. Leaflet Thrombosis in Bioprosthetic Aortic Valves: Clinical Outcomes . Stanton J Rowe. CEO. NXT Biomedical. I, Stanton Rowe, DO have a financial interest/arrangement . or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.. ”. Muhammad Raza, MD, FACC, FSCAI, RPVI.. Interventional cardiologist. Director, Cardiac Cath Lab, . Crozer. Chester Medical Center,. Upland, PA. . Disclosure. Consultant and Proctor – Medtronic. Shilpa Shelton, MBA. Program Director, . Bluhm. Cardiovascular Institute. Northwestern Medicine. “Back to the Basics: Coding, Documentation, Coverage”. Disclaimer. The information provided is the experience of the . Nicolas M. Van Mieghem, MD, PhD. For the SURTAVI Trial . Investigators. 0. Disclosure Statement of Financial Interests. Within the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) list below. Medical Director, . Resp. Care. Lodi Memorial Hospital. Assoc. . Clin. Prof Medicine. UC Davis . STROKE. Acute brain disorder of vascular origin accompanied by neurological dysfunction that persists for longer than 24 hours…. A Heart Team Perspective. Interventional cardiology: . Megan Coylewright, MD MPH FSCAI. Dartmouth-Hitchcock Heart and Vascular Center. Cardiac surgery: . Melissa Levack, MD. Vanderbilt University Medical Center. What effect does glycemic control with insulin have on these complications?. None. . Insulin does not improve mortality rates/neurological outcomes after stroke. Why do we care?. Stroke is the 5. th. Low-risk Randomized Trial. Michael J. Mack, . MD & . Martin B. Leon, MD. on behalf of the PARTNER 3 Trial Investigators. Disclosures - Michael J. Mack, MD. ACC 2020; Chicago, IL; March 28–30, 2020. Evolut. Low Risk Bicuspid Study. Basel Ramlawi, MD, FACC. Valley Health System, Winchester, Virginia. For the . Evolut. Low Risk Bicuspid Investigators. Disclosure Statement of Financial Interests.